Biotech Director Compensation: Rapport Board Member Gets 10,925 Share Option Grant

Rhea-AI Filing Summary

Director Paul M. Silva of Rapport Therapeutics received a stock option grant for 10,925 shares of common stock on June 17, 2025. The options were granted with the following key terms:

• Exercise price set at $10.95 per share
• Expiration date of June 17, 2035
• Vesting occurs at earlier of:
  • June 17, 2026
  • Next Annual Meeting of Stockholders

The options were granted at $0 cost to the director and will vest subject to continued service. This represents standard director compensation aligned with the company's equity incentive practices. The Form 4 was filed by Troy Ignelzi as attorney-in-fact on June 18, 2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Silva Paul M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,925	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,925 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silva Paul M

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.95	06/17/2025		A		10,925		(1)	06/17/2035	Common Stock	10,925	$0	10,925	D

Explanation of Responses:

1. The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did RAPP director Paul Silva receive on June 17, 2025?

Paul Silva received 10,925 stock options with an exercise price of $10.95 per share. These options represent the right to buy RAPP common stock and were granted on June 17, 2025, with an expiration date of June 17, 2035.

When do Paul Silva's RAPP stock options vest?

The stock options will vest upon the earlier of two conditions: (i) June 17, 2026, or (ii) the date of RAPP's next Annual Meeting of Stockholders, subject to Silva's continued service as a director until the vesting date.

What position does Paul Silva hold at RAPP Therapeutics?

According to the Form 4 filing, Paul Silva serves as a Director of Rapport Therapeutics, Inc. (RAPP). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.

What is the total value of RAPP stock options granted to Paul Silva?

The Form 4 shows that Paul Silva received 10,925 stock options at an exercise price of $10.95 per share. The options were granted at $0 cost to Silva, as indicated in the 'Price of Derivative Security' column, representing standard compensation for his role as a director.